chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Joint pain; congestion; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: EP6955) via an unspecified route of administration in the left arm on 08Apr2021 at 15:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included thyroid disease. Concomitant medications included levothyroxine sodium (SYNTHROID) since an unknown date for an unknown indication. The patient previously took BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: EP6955) via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient had no known allergies to food, medications or other products. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 09Apr2021, day after the second dose of vaccination at 10:00 the patient experienced joint pain and congestion. The patient did not receive any treatment for the event. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events joint pain and congestion was not recovered at the time of  this report.   No follow-up attempts are needed. No further information is expected.
after recv vax pt on same day devel fever 104, was irritable. over next few wk rash began to worsen to chronic urticaria & vasculitis. pt sought m.d. attention & lab tests done on pt
chills; body aches; skin rash; fever; This spontaneous report was received from a other health professional via company representative regarding to a 11 year old male patient. The patient's medical history, concurrent condition and concomitant medications were not reported. On 08-FEB-2019, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II), lot # N014482 and expiry date 10-MAY-2019, (strength, dose, frequency, route was not reported) for prophylaxis. Other suspect therapies included sterile diluent. The reporter described that, on 08-FEB-2019, (also reported possibly two days after vaccine was administered), the patient was developed skin rash (rash), fever (pyrexia), body aches (pain), chills. The reporter stated that on an unspecified date, the patient was performed blood test which was showed results antibodies, measles, polymerase chain reaction, rubella, and immunoglobulins. The patient had sought medical attention. The outcome of chills, pyrexia, rash and pain was unknown. The causality assessment between measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) and sterile diluent and events were not provided.
Red; It felt hot; Bright rash 3inches wide by 3.5inches length; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Red), FEELING HOT (It felt hot) and RASH (Bright rash 3inches wide by 3.5inches length) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, the patient experienced ERYTHEMA (Red), FEELING HOT (It felt hot) and RASH (Bright rash 3inches wide by 3.5inches length). At the time of the report, ERYTHEMA (Red), FEELING HOT (It felt hot) and RASH (Bright rash 3inches wide by 3.5inches length) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment for the events included cephalexin (500 mg PO for 10 days).
Diagnosed with pulmonary embolism on 4/28/21, 11 days after receiving the 2nd dose of the vaccine.
Shot given on 10/12/13 at 5AM, patient reported with redness beyond the site of injection, very hot to the touch and extremely painful. She said she could not move her arm from the pain.
the following day after the vaccine I woke up with severe upper leg muscle pain, joint pain thru my whole body, severe headache with nausea, fatigue, my cheeks appeared wind burnt, I had extreme chills with shaking due to feeling so cold and felt feverish, no fever registered on a thermometer though. I had all these symptoms  for  approx. 24 hours with feelings of severe flu.
After vaccination mom reports the pt was very lethargic. Arm was swollen and had a white spot where vaccine was given. Eyes were sensitive to lights and had a headache.
postherpetic neuralgia; scars; multiple outbreaks of herpes zoster; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently approximately 74-year-old patient of unknown gender. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or about 22-NOV-2016, the patient was administered the zoster vaccine live (ZOSTAVAX) (dose, dose#, route and anatomical location, lot# and expiration date were not specified) by a physician at the clinic for the long-term prevention of shingles and zoster-related conditions. Subsequently, on an unspecified date, the patient was treated by providers for the following injuries resulting from the patient's zoster vaccine live (ZOSTAVAX) use: multiple outbreaks of herpes zoster, postherpetic neuralgia and scars. The outcome of the events was not reported. The reporter considered the events to be related to zoster vaccine live (ZOSTAVAX).
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a patient of unknown age and gender. No information was provided regarding patient's concomitant medications, concurrent conditions or medical history. On or about 05-APR-2013, the patient was vaccinated with ZOSTAVAX (strength, dose, route, anatomical location, lot number and expiration date were not reported), to obtain permanent prevention and protection against shingles and zoster-related injuries (prophylaxis) as recommended by the healthcare professional. On an unknown date, the patient experienced shingles (Herpes zoster) and on or about 09-NOV-2016, was treated by healthcare providers at a medical clinic. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX (Vaccination failure) and suffered serious physical, emotional, and economic damages (Emotional distress), as a result of patient's injuries on unknown dates. The patient had and would continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering (Emotional distress) (Pain); extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs included care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (Condition aggravated); lost wages; loss of earnings capacity; and other losses and damages. At the time of the report, the patient was not recovered from emotional distress and pain, and the outcome of the patient regarding the vaccination failure, herpes zoster, quality of life decreased and the pre-existing unspecified conditions aggravated was unknown. The relatedness between ZOSTAVAX and the aforementioned events was assessed as related by the reporter. The reporter determined all the events to be serious due to disability, life-threatening and medically significant.
Information has been received from a nurse referring to multiple, unspecified patients of unknown ages and genders. Information of concurrent condition, pertinent medical history, concomitant medication and drug reactions/allergies were not provided. From June 2018 to October 2018, multiple, unspecified patients received improperly stored doses of VAQTA (dose, frequency, route were unknown; therapy type: digital data logger; lot number N030287 with expiration date 22-JAN-2019; lot number N020951 with expiration date 15-OCT-2018); PNEUMOVAX 23 (dose, frequency, route were unknown; therapy type: digital data logger; lot number R002085 with expiration date 26-OCT-2019; lot number N030847 with expiration date 09-JUN-2018); ROTATEQ (dose, frequency, route were unknown; therapy type: digital data logger; lot number N004815 with expiration date 07-OCT-2019); M-M-R II (dose, frequency, route were unknown; therapy type: digital data logger; lot number N024698 with expiration date 08-SEP-2019; lot number N025889  with expiration date 18-APR-2019; lot number M045394 with expiration date 14-NOV-2018) and VARIVAX (dose, frequency, route were unknown; therapy type: digital data logger; lot number N035937 with expiration date 18-DEC-2019; lot number N030410 with expiration date 30-OCT-2019; lot number N019127 with expiration date 22-JUN-2019; lot number N017698 with expiration date 09-JUN-2019) with sterile diluent (MERCK) for prophylaxis. VAQTA, PNEUMOVAX 23, M-M-R II and ROTATEQ were exposed to temperature excursion of 9 degree centigrade to 25 degree centigrade for 1 hour and 30 minutes. VARIVAX were exposed to temperature excursion of -14 degree centigrade to -10 degree centigrade for 1 hour and 30 minutes. There was no previous temperature excursion. At the time of reporting, ROTATEQ was expired but they were not expired when administered to an unspecified patient. The sterile diluent (manufacturer unknown) used to reconstitute M-M-R II and VARIVAX was properly stored. No adverse effects were reported. This case was determined to be non-valid as no patient identifier.
This spontaneous report was received from a pharmacist refers to a 41 year old patient. Medical history and concurrent conditions were not reported. On 08-OCT-2014, the patient was vaccinated with a dose of ZOSTAVAX (dose number, lot number and expiration date were not reported) (dose reported as 1 single shot), subcutaneous. Co -suspect and concomitant therapies were not reported. The pharmacist reported, patient was scheduled to receive (Oka/Merck) VARIVAX but was accidentally given ZOSTAVAX, on 08-OCT-2014, and now she had to wait even longer to try to conceive a child. No adverse effects were reported.  Additional information has been requested.
knot has appeared at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE MASS (knot has appeared at the injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028620A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INJECTION SITE MASS (knot has appeared at the injection site). At the time of the report, INJECTION SITE MASS (knot has appeared at the injection site) had resolved.            Concomitant information not provided. Treatment information not provided   Most recent FOLLOW-UP information incorporated above includes: On 20-Jul-2021: Follow up received. Event outcome updated. Second dose information picked from initial source document and action taken with suspect product updated accordingly.
He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now; He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now; This spontaneous case was reported by a patient and describes the occurrence of VERTIGO (He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now) and DIZZINESS (He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 20-Jan-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 28-Jan-2023, the patient experienced VERTIGO (He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now) and DIZZINESS (He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now). At the time of the report, VERTIGO (He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now) and DIZZINESS (He took it on 20JAN2023 and started having dizzy spells about 8 days later that just progressed to vertigo, dizziness, and he has been on his back for about 5 days now) had not resolved.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medications were provided.
This infant had bilateral otitis media, fever, bacteremia, streptococcus pneumoniae, strep pneumo AG positive, gram, positive cocci in pairs in chains.
Blacked out/Was out for over 2 minutes; This is a spontaneous report received from a contactable consumer (patient). A 46-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number ER8733, on 30Mar2021 15:45 at single dose in left arm for Covid-19 immunization. Medical history was none. Concomitant medications were none. The patient previously received barium and had Allergies. The patient had no other vaccine in four weeks. The patient had no covid prior vaccination. The patient had no covid tested post vaccination. The patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. The patient was Blacked out on 30Mar2021 15:45 and was taken to hospital by ambulance. Was out for over 2.minutes. No other reaction. Duration of hospitalization was 1 day. The event resulted in Emergency Room Visit and Physician Office Visit. No treatment was received. The outcome of the event was resolved.
PAPULAR RASH/DERMATITIS AFFECTING BOTH UPPER EXTREMITIES, NECK AND BEHIND EARS, HAPPENED 3.5 HOURS AFTER THE DOSE
Itching on the Injection Site; redness on the injection site; Rash with bumps on the Injection Site; Swelling on the Injection Site; Tenderness Injection Site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Rash with bumps on the Injection Site) and VACCINATION SITE SWELLING (Swelling on the Injection Site) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced VACCINATION SITE RASH (Rash with bumps on the Injection Site) and VACCINATION SITE SWELLING (Swelling on the Injection Site). The patient was treated with HYDROCORTISONE for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (Rash with bumps on the Injection Site) and VACCINATION SITE SWELLING (Swelling on the Injection Site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not reported
Spoke with RN with Pfizer and staff regarding pfiizer vaccine that was adminstered to pt on 1/3/22 per immunizations due to vial was expired as of 12/31/21. Per RN there is a 32 day max on vials that are refrigerated. Staff Medical information told nurse  to contact cdc to discuss 2nd step. Also contacted CDC and spoke with staff and recommended for pt to get re-vaccinated due to expired vaccine. Pt has no c/o adverse effects at this time.
2/12/21 - Recieved the Covid 19 vaccine 2/13/21 - 5 pm.  Fever, chills, no appetite, no taste, no smell, fatigue - was gone by 8 am the next day.  Took Tyenol and rest.  Taste and smell returned.  2/14/21 - 5 pm.  Was eating and had a sip of wine.  Felt like I was choking and had a strange sensation in the head.  Felt like I blacked out for 2 seconds and was drolling.  This is the only time that I have experienced this.
PATIENT PRESENTED TO OFFICE ON 07/22/11 WITH A 3CM X 3CM AREA OF MILD REDNESS AND TENDERNEDSS NOTED ON THE LEFT UPPER ARM AT VACCINATION SITE.
itchy rash; rash on back of neck; This spontaneous case was reported by a physician and describes the occurrence of RASH PRURITIC (itchy rash) and RASH (rash on back of neck) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     Concurrent medical conditions included Lupus erythematosus (reported that patient had lupus). Concomitant products included HYDROCORTISONE and PREDNISONE for an unknown indication.   On 29-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Jan-2021, the patient experienced RASH PRURITIC (itchy rash) and RASH (rash on back of neck). At the time of the report, RASH PRURITIC (itchy rash) and RASH (rash on back of neck) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment details were not reported by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 14-Apr-2021: Follow up was received and case is NNI.
Beginning June 1st I have had vertigo every morning, it is going on 2 weeks now. I have no other symptoms that would lead to believe I have an infection of any kind.
Febrile with shaking chills, fatigue, dripping cold sweat,fatigue lasting days
pt was adm to hosp on 20APR96 for ITP;21APR96 plt count 3,000;pt recv 2 doses IVIG-plt up to 75,000 on d/c;cont to be followed by MD
A report has been received from a health professional via medical representative concerning a female patient. This case reports for one of the four patients from same reporter. No information regarding relevant history, concurrent disease and concomitant medications of the patient was provided. The patient was receiving FLUMIST (intranasal) started in Aug-2012 or Sep-2012. The reporter stated that he had an office that reported four employees who got FLUMIST last season and FLUMIST did not protect them from getting the flu. The employees tested positive for the flu after receiving FLUMIST. Further it was reported that the patient received FLUMIST in Aug-2012 or Sep-2012 and became ill in October. Reporter stated that flu lasted for about three days. Action taken with FLUMIST was unknown. The patient recovered from the event of patient tested positive for flu after receiving FLUMIST and had the flu on an unspecified date. The report was considered to be non-serious by company physician.
Pt started w/symptoms in the evening vaccines were administered. Symptoms are musculoskeletal pain, sweats, headaches, dizziness redness on left deltoid. Recommended ibuprofen, increase fluid intake, rest review ER precautions.
Tachycardia; Rash; Chronic fevers; Severe fatigue; swelling of throat; This is a spontaneous report received from a contactable reporter (Other healthcare professional). The reporter is the patient.  A 33-year-old female patient (not pregnant) received bnt162b2 (BNT162B2) on 30Oct2021 at 17:00 as dose 1, single (Lot number: 301308A), at the age of 33 years, in left arm, for COVID-19 immunisation. Relevant medical history included: "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, was the patient diagnosed with COVID-19: Yes. The patient did not receive any concomitant medications. Past drug history included: Erythromycin, reaction: "Drug allergy", notes: known allergies: Erythromycin.  The following information was reported: TACHYCARDIA (non-serious) with onset 30Oct2021, outcome "recovered with sequelae"; RASH (non-serious) with onset 30Oct2021, outcome "recovered with sequelae"; PYREXIA (non-serious) with onset 30Oct2021, outcome "recovered with sequelae", described as "Chronic fevers"; FATIGUE (non-serious) with onset 30Oct2021, outcome "recovered with sequelae", described as "Severe fatigue"; PHARYNGEAL SWELLING (non-serious) with onset 30Oct2021, outcome "recovered with sequelae", described as "swelling of throat". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of tachycardia, rash, pyrexia, fatigue and pharyngeal swelling.  Additional information: Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The events Tachycardia, rash, chronic fevers, severe fatigue, swelling of throat were evaluated at the physician office visit. Treatment included Benadryl received within 5 minutes after vaccination for TACHYCARDIA, RASH, PYREXIA, FATIGUE and PHARYNGEAL SWELLING . Since the vaccination, the patient had been tested for COVID-19. The patient also received bnt162b2 (BNT162B2) on 28Nov2021 at 10:15 as dose 2, single (Lot number: FF8839) in right arm, for COVID-19 immunisation.